Insider Selling: Charles River Laboratories Intl. Inc (CRL) Chairman Sells 4,967 Shares of Stock

Charles River Laboratories Intl. Inc (NYSE:CRL) Chairman James C. Foster sold 4,967 shares of the stock in a transaction that occurred on Tuesday, January 2nd. The shares were sold at an average price of $109.44, for a total value of $543,588.48. Following the transaction, the chairman now directly owns 329,928 shares of the company’s stock, valued at $36,107,320.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Shares of Charles River Laboratories Intl. Inc (CRL) traded down $0.62 during trading on Thursday, hitting $109.85. The stock had a trading volume of 416,700 shares, compared to its average volume of 320,814. Charles River Laboratories Intl. Inc has a fifty-two week low of $77.61 and a fifty-two week high of $119.05. The firm has a market cap of $5,200.00, a PE ratio of 26.86, a P/E/G ratio of 1.64 and a beta of 0.88. The company has a current ratio of 1.88, a quick ratio of 1.62 and a debt-to-equity ratio of 1.13.

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings data on Thursday, November 9th. The medical research company reported $1.30 EPS for the quarter, beating analysts’ consensus estimates of $1.22 by $0.08. Charles River Laboratories Intl. had a return on equity of 26.58% and a net margin of 10.72%. The firm had revenue of $464.23 million for the quarter, compared to analysts’ expectations of $458.93 million. During the same period in the prior year, the firm posted $1.18 earnings per share. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. research analysts forecast that Charles River Laboratories Intl. Inc will post 5.14 earnings per share for the current fiscal year.

Hedge funds and other institutional investors have recently made changes to their positions in the business. YorkBridge Wealth Partners LLC raised its position in Charles River Laboratories Intl. by 445.5% in the third quarter. YorkBridge Wealth Partners LLC now owns 1,091 shares of the medical research company’s stock valued at $118,000 after purchasing an additional 891 shares during the period. Ladenburg Thalmann Financial Services Inc. increased its position in shares of Charles River Laboratories Intl. by 69.0% during the third quarter. Ladenburg Thalmann Financial Services Inc. now owns 1,342 shares of the medical research company’s stock worth $145,000 after acquiring an additional 548 shares during the period. Advisor Group Inc. increased its position in shares of Charles River Laboratories Intl. by 159.4% during the third quarter. Advisor Group Inc. now owns 1,538 shares of the medical research company’s stock worth $165,000 after acquiring an additional 945 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Charles River Laboratories Intl. by 12.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,791 shares of the medical research company’s stock worth $181,000 after acquiring an additional 202 shares during the period. Finally, Riverhead Capital Management LLC increased its position in shares of Charles River Laboratories Intl. by 14.7% during the second quarter. Riverhead Capital Management LLC now owns 1,931 shares of the medical research company’s stock worth $195,000 after acquiring an additional 247 shares during the period. 95.80% of the stock is currently owned by institutional investors.

CRL has been the topic of several recent analyst reports. Royal Bank of Canada initiated coverage on Charles River Laboratories Intl. in a report on Tuesday, September 19th. They issued a “sector perform” rating and a $110.00 price target on the stock. Jefferies Group raised their price objective on Charles River Laboratories Intl. from $120.00 to $130.00 and gave the stock a “buy” rating in a report on Monday, October 9th. Credit Suisse Group restated a “neutral” rating and set a $112.00 price objective (up from $95.00) on shares of Charles River Laboratories Intl. in a report on Monday, October 16th. Zacks Investment Research raised Charles River Laboratories Intl. from a “hold” rating to a “buy” rating and set a $129.00 target price on the stock in a research report on Tuesday, October 24th. Finally, Bank of America dropped their target price on Charles River Laboratories Intl. from $117.00 to $115.00 and set a “buy” rating on the stock in a research report on Friday, November 10th. Six research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $112.36.

TRADEMARK VIOLATION WARNING: This piece was originally published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece on another site, it was illegally copied and republished in violation of US & international copyright law. The legal version of this piece can be read at https://www.dispatchtribunal.com/2018/01/11/insider-selling-charles-river-laboratories-intl-inc-crl-chairman-sells-4967-shares-of-stock.html.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development.

Insider Buying and Selling by Quarter for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply